|本期目录/Table of Contents|

[1]陈昕涛,高倩闽,李明明综述,等.个体化用药方案在结直肠癌患者化疗中的临床应用进展[J].医学研究与战创伤救治(原医学研究生学报),2020,22(01):65-70.[doi:10.3969/j.issn.1672-271X.2020.01.015]
　CHENXin-tao,GAO Qian-min,LI Ming-ming reviewing,et al.Progress in clinical application of individualized drugs in the treatment of colorectal cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2020,22(01):65-70.[doi:10.3969/j.issn.1672-271X.2020.01.015]
点击复制

个体化用药方案在结直肠癌患者化疗中的临床应用进展()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第22卷
期数:
2020年01期
页码:
65-70
栏目:
综述
出版日期:
2020-01-06

文章信息/Info

Title:
Progress in clinical application of individualized drugs in the treatment of colorectal cancer
作者:
陈昕涛; 高倩闽; 李明明综述; 位 华审校
作者单位：200433 上海，海军军医大学基础医学院学员四大队（陈昕涛、高倩闽）；200003 上海，海军军医大学附属上海长征医院药材科（李明明、位 华）
Author(s):
CHEN　Xin-tao1;  GAO Qian-min1;  LI Ming-ming2 reviewing;  WEI Hua2 checking
（1.Fourth Brigades of Basic Medical College, Naval Military Medical University, Shanghai 200433, China； 2.Department of Pharmaceutical, Shanghai Changzheng Hospital, Naval Military Medical University, Shanghai 200003, China）
关键词:
个体化; 结直肠癌; 基因多肽; 毒性反应; 药物动力学
Keywords:
individualization;  colorectal cancer;  gene polypeptide;  toxicity;  pharmacokinetics
分类号:
R735.3
DOI:
10.3969/j.issn.1672-271X.2020.01.015
文献标志码:
A
摘要:
结直肠癌（CRC）是临床较常见的恶性肿瘤之一，给社会与个人带来巨大的医疗负担。细胞毒性化疗仍然是CRC患者的重要治疗手段，一线化疗药物包括5-氟尿嘧啶类药物、伊立替康等。虽然药物疗效确切，但患者间有效性与安全性存在较大差异。近年来，针对结直肠癌个体化化疗的研究发展迅速，发现了基因多态性、DNA甲基化、miRNA、内源性代谢物等多种生物标志物，有力促进了CRC的个体化化疗，但由于绝大多数标志物的应用是基于回顾性的研究，距离真正指导临床用药仍有一定距离，开展有针对性的前瞻性研究有利于CRC个体化化疗的进一步发展。文章主要通过对基于生物标志物制定个体化化疗方案治疗CRC的前瞻性临床研究进行综述。
Abstract:
Colorectal cancer (CRC) is one of the more common malignant tumors in the clinic, which brings huge medical burden to society and individuals. Cytotoxic chemotherapy is still an important treatment for patients with CRC. First-line chemotherapy drugs include 5-fluorouracil and irinotecan. Although the efficacy is exact, there is a large difference in efficacy and safety between patients. In recent years, research on individualized chemotherapy for colorectal cancer has developed rapidly, and various biomarkers such as gene polymorphism, DNA methylation, miRNA, and endogenous metabolites have been discovered, which has effectively promoted the individualization of CRC. However, since the application of most markers is based on retrospective studies, there is still a certain distance from the true guidance of clinical medication. Conducting targeted, prospective studies are conducive to the further development of CRC individualized chemotherapy. Conducting targeted, prospective studies are conducive to the further development of CRC individualized chemotherapy. This article mainly reviews the prospective clinical research on the treatment of CRC with individualized chemotherapy based on biomarkers.

参考文献/References:

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(suppl 12): 7-34.[2] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. Ca Cancer J Clin, 2016, 66(2): 115-132.[3] Benson AB, Venook AP, Al-Hawary MM, et al. NCCN Guidelines Insights: Colon Cancer, Version 2.2018[J]. J Natl Compr Canc Netw, 2018, 16(4): 359-369.[4] Sveen A, Bruun J, Eide PW, et al. Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies[J]. Clin Cancer Res, 2018, 24(4): 794-806.[5] James C, Tadeusz P, David R, et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer[J]. J Clin Oncol, 2002, 20(17): 3617-3627.[6] Mikhail SE, Sun JF, Marshall JL. Safety of capecitabine: a review[J]. Expert Opin Drug Saf, 2010, 9(5): 831-841.[7] Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study[J]. J Clin Oncol, 2001, 19(21): 4097-4106.[8] Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803[J]. J Clin Oncol, 2007, 25(23): 3456-3461.[9] Rosmarin D, Palles C, Pagnamenta A, et al. A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS[J]. Gut, 2015, 64(1): 111-120.[10] Sobrero A, Guglielmi A, Grossi F, et al. Mechanism of action of fluoropyrimidines: relevance to the new developments in colorectal cancer chemotherapy[J]. Semin Oncol, 2000, 27(5 Suppl 10): 72-77.[11] Poon M A, O’Connell MJ, Wieand HS, et al. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer[J]. J Clin Oncol, 1991, 9(11): 1967-1972.[12] Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies[J]. Nat Rev Cancer, 2003, 3(5): 330-338.[13] 张凤, 陈万生. 励精图治——代谢组学在精准化药物治疗中的角色[J]. 医学研究生学报, 2019, 32(5): 484-489.[14] Carmichael J, Popiela T, Radstone D, et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer[J]. J Clin Oncol, 2002, 20(17): 3617-3627.[15] Morawska K, Goirand F, Marceau L, et al. 5-FU therapeutic drug monitoring as a valuable option to reduce toxicity in patients with gastrointestinal cancer[J]. Oncotarget, 2018, 9(14): 11559-11571.[16] Patel JN, O’Neil BH, Deal AM, et al. A community-based multicenter trial of pharmacokinetically guided 5-fluorouracil dosing for personalized colorectal cancer therapy[J]. Oncologist, 2014, 19(9): 959-965.[17] Meulendijks D, Henricks LM, Jacobs BAW, et al.Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity[J]. Br J Cancer, 2017, 116(11): 1415-1424.[18] Mattison LK, Fourie J, Desmond RA, et al. Increased Prevalence of Dihydropyrimidine Dehydrogenase Deficiency in African-Americans Compared with Caucasians[J]. Clin Cancer Res, 2006, 12(18): 5491-5495.[19] Vreken P, Van Kuilenburg AB, Meinsma R, et al. A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency[J]. J Inherit Metab Dis, 1996, 19(5): 645-654.[20] Johnson MR, Diasio RB. Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil[J]. Adv Enzyme Regul, 2001, 41（1）: 151-157.[21] Deenen MJ, Meulendijks D, Cats A, et al. Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis[J]. J Clin Oncol, 2016, 34(3): 227-234.[22] Kawakami K, Salonga D, Park JM, et al. Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression[J]. Clin Cancer Res, 2001, 7(12): 4096-4101.[23] Marsh S, Collie-Duguid ES, Li T, et al. Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations[J]. Genomics, 1999, 58(3): 310-312.[24] Soo RA, Syn N, Lee SC, et al. Pharmacogenetics-Guided Phase I Study of Capecitabine on an Intermittent Schedule in Patients with Advanced or Metastatic Solid Tumours[J]. Sci Rep, 2016, 6（1）: 27826.[25] Freyer G, Duret A, Milano G, et al. Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study[J]. Anticancer Res, 2011, 31(1): 359-366.[26] Yeh YS, Tsai HL, Huang CW, et al. Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial[J]. Trials, 2016, 17（1）：46.[27] Hoskins JM, Goldberg RM, Qu P, et al. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters[J]. J Natl Cancer Inst, 2007, 99(17): 1290-1295.[28] Iyer L, Hall D, Das S, et al. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism[J]. Clin Pharmacol Ther, 1999, 65(5): 576-582.[29] Toffoli G, Sharma MR, Marangon E, et al. Genotype-guided dosing study of FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer[J]. Clin Cancer Res, 2017, 23(4): 918-924.[30] Ochiai T, Nishimura K, Watanabe T, et al. Impact of the individualization of the first-line chemotherapy for advanced colorectal cancer based on collagen gel droplet-embedded drug sensitivity test[J]. Oncol Lett, 2017, 14(5): 6045-6052.[31] Sveen A, Bruun J, Eide PW, et al. Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies[J]. Clin Cancer Res, 2018, 24(4): 794-806.[32] Etienne-Grimaldi MC, Boyer JC, Beroud C, et al. New advances in DPYD genotype and risk of severe toxicity under capecitabine[J]. PloS One, 2017, 12(5): e0175998.[33] 张凤, 陶霞, 位华, 等. 精准化药物治疗实现路径思考与探索[J]. 中国医院药学杂志, 2018, 38(9): 907-911.

相似文献/References:

[1]李丙军,丁江华,洪建明.卡培他滨节拍化疗治疗转移性结直肠癌22例[J].医学研究与战创伤救治(原医学研究生学报),2010,12(03):247.
[2]王莉娜,高 静.西妥昔单抗致甲沟炎的护理体会[J].医学研究与战创伤救治(原医学研究生学报),2010,12(04):354.
[3]陈昌浩,孙岳军,王建东.受体酪氨酸激酶EphB6蛋白在结直肠癌中表达及临床意义[J].医学研究与战创伤救治(原医学研究生学报),2016,18(04):346.[doi:10.3969/j.issn.1672-271X.2016.04.003]
　CHEN Chang-hao,SUN Yue-jun,WANG Jian-dong..Clinical significance of decreased expression of EphB6 receptor tyrosine kinase in colorectal carcinoma[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2016,18(01):346.[doi:10.3969/j.issn.1672-271X.2016.04.003]
[4]陈昕涛综述,姚厚山审校.结直肠癌腹腔镜手术治疗的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2020,22(3):283.[doi:10.3969/j.issn.1672-271X.2020.03.013]
　CHEN Xin-tao reviewing,YAO Hou-shan checking.Progress of laparoscopic surgery for colorectal cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2020,22(01):283.[doi:10.3969/j.issn.1672-271X.2020.03.013]
[5]张嘉琦,贾佩琦,苏东明.染色盒同源物3对人结直肠癌细胞增殖的影响及其机制研究[J].医学研究与战创伤救治(原医学研究生学报),2021,23(01):6.[doi:10.3969/j.issn.1672-271X.2021.01.001]
　ZHANG Jia-qi,JIA Pei-qi,SU Dong-ming.The effect of CBX3 on the biological behavior of human colorectal cancer cells and its mechanism[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2021,23(01):6.[doi:10.3969/j.issn.1672-271X.2021.01.001]

备注/Memo

备注/Memo:
基金项目：上海申康医院发展中心临床科技创新项目（SHDC12015120）
更新日期/Last Update: 2020-01-06